» Articles » PMID: 38486992

Metal Nanoparticles for Cancer Therapy: Precision Targeting of DNA Damage

Overview
Publisher Elsevier
Specialty Pharmacology
Date 2024 Mar 15
PMID 38486992
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer, a complex and heterogeneous disease, arises from genomic instability. Currently, DNA damage-based cancer treatments, including radiotherapy and chemotherapy, are employed in clinical practice. However, the efficacy and safety of these therapies are constrained by various factors, limiting their ability to meet current clinical demands. Metal nanoparticles present promising avenues for enhancing each critical aspect of DNA damage-based cancer therapy. Their customizable physicochemical properties enable the development of targeted and personalized treatment platforms. In this review, we delve into the design principles and optimization strategies of metal nanoparticles. We shed light on the limitations of DNA damage-based therapy while highlighting the diverse strategies made possible by metal nanoparticles. These encompass targeted drug delivery, inhibition of DNA repair mechanisms, induction of cell death, and the cascading immune response. Moreover, we explore the pivotal role of physicochemical factors such as nanoparticle size, stimuli-responsiveness, and surface modification in shaping metal nanoparticle platforms. Finally, we present insights into the challenges and future directions of metal nanoparticles in advancing DNA damage-based cancer therapy, paving the way for novel treatment paradigms.

Citing Articles

An Evaluation of the Potential Radiosensitization Effect of Spherical Gold Nanoparticles to Induce Cellular Damage Using Different Radiation Qualities.

Engelbrecht-Roberts M, Miles X, Vandevoorde C, de Kock M Molecules. 2025; 30(5).

PMID: 40076263 PMC: 11902069. DOI: 10.3390/molecules30051038.


Recent advances in reactive oxygen species (ROS)-responsive drug delivery systems for photodynamic therapy of cancer.

Hu D, Li Y, Li R, Wang M, Zhou K, He C Acta Pharm Sin B. 2025; 14(12):5106-5131.

PMID: 39807318 PMC: 11725102. DOI: 10.1016/j.apsb.2024.10.015.


Metabolic-Modulating Effects of Radiation: Undetectable Yet Deadly-A Review on Radiotherapy.

Fiorica F, Tebano U, Napoli G, Franceschetto A, Muraro M, Giorgi C Cancers (Basel). 2025; 17(1.

PMID: 39796683 PMC: 11719003. DOI: 10.3390/cancers17010054.


Enhancing cancer therapy: advanced nanovehicle delivery systems for oridonin.

Su Y, Liu L, Lin C, Deng D, Li Y, Huang M Front Pharmacol. 2024; 15:1476739.

PMID: 39691396 PMC: 11649421. DOI: 10.3389/fphar.2024.1476739.


Next-generation aluminum adjuvants: Immunomodulatory layered double hydroxide NanoAlum reengineered from first-line drugs.

Su Z, Boucetta H, Shao J, Huang J, Wang R, Shen A Acta Pharm Sin B. 2024; 14(11):4665-4682.

PMID: 39664431 PMC: 11628803. DOI: 10.1016/j.apsb.2024.09.012.

References
1.
Roos W, Thomas A, Kaina B . DNA damage and the balance between survival and death in cancer biology. Nat Rev Cancer. 2015; 16(1):20-33. DOI: 10.1038/nrc.2015.2. View

2.
Irvine D, Dane E . Enhancing cancer immunotherapy with nanomedicine. Nat Rev Immunol. 2020; 20(5):321-334. PMC: 7536618. DOI: 10.1038/s41577-019-0269-6. View

3.
Zhang H, Chen B, Jiang H, Wang C, Wang H, Wang X . A strategy for ZnO nanorod mediated multi-mode cancer treatment. Biomaterials. 2010; 32(7):1906-14. DOI: 10.1016/j.biomaterials.2010.11.027. View

4.
DeGorter M, Xia C, Yang J, Kim R . Drug transporters in drug efficacy and toxicity. Annu Rev Pharmacol Toxicol. 2011; 52:249-73. DOI: 10.1146/annurev-pharmtox-010611-134529. View

5.
Xia H, Li F, Hu X, Park W, Wang S, Jang Y . pH-Sensitive Pt Nanocluster Assembly Overcomes Cisplatin Resistance and Heterogeneous Stemness of Hepatocellular Carcinoma. ACS Cent Sci. 2016; 2(11):802-811. PMC: 5126722. DOI: 10.1021/acscentsci.6b00197. View